



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT  
SECOND QUARTER OF 2023 (2023Q2)**

**Substance Use Epidemiology Section  
Prescription Drug Overdose Prevention Program  
Injury and Behavioral Epidemiology Bureau  
Epidemiology and Response Division**

This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.

Data for this report were drawn from several sources:



1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites.
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

Reports for 2020 Q2 and after reflect a changed definition of medication assisted treatment (MAT). The older definition defined MAT as buprenorphine/naloxone combination products only. The new definition has been applied to all quarters included in this report and includes all buprenorphine products except a couple of types indicated for the treatment of pain. Because MAT products are usually high-dose prescriptions and are counted separately from other opioids, this change has an effect on many of the indicators in this report.




Prior to 2020 Q4, a number of controlled substances were excluded from the analyses that are the basis of this report. These included the barbiturates and some miscellaneous controlled substances (notably testosterone and pregabalin). The inclusion of these drugs increased the number of controlled substance patients and providers reported, and increased the number of patients with multiple providers or pharmacies. Most other indicators were not affected.

Gabapentin was added to PMP reporting as a drug of concern in March 2023. This caused increases in the number of prescribers with 20+ patients, the number of patients with multiple providers. Most other indicators were not affected.

## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Totals

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
Total number of controlled substance patients	219,886	220,155	220,086	0.0%	0.1%
Number of patients receiving opioids (excluding MAT)	114,672	113,497	111,589	-1.7%	-2.7%
Number of opioid prescriptions filled (excluding MAT)	241,277	237,620	233,953	-1.5%	-3.0%
Number of MAT buprenorphine prescriptions filled	28,780	28,460	28,323	-0.5%	-1.6%
Number of high dose ( $\geq 90$ MME/day) opioid prescriptions (excluding MAT)	19,647	19,050	18,686	-1.9%	-4.9%
Total MME of opioids filled - (excluding MAT)	169,140,684	161,525,634	159,963,334	-1.0%	-5.4%
Total MME/prescription-day	44	43	43	-0.7%	-2.4%
Number of patients receiving benzodiazepines	67,238	65,980	65,786	-0.3%	-2.2%
Number of benzodiazepine prescriptions filled	144,917	140,480	139,326	-0.8%	-3.9%
Number of high-dose( $\geq 40$ DME/day) benzodiazepine prescriptions filled	21,954	20,657	20,518	-0.7%	-6.5%
Total DME of benzodiazepines filled	68,259,156	63,890,435	63,252,064	-1.0%	-7.3%
Total DME/patient	1,015	968	961	-0.7%	-5.3%

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MAT = Medication assisted treatment - the use of buprenorphine products indicated for treatment of opioid use disorder. Excludes products indicated for the treatment of pain.

MME = Morphine Milligram Equivalent; reference at [http://www.cdc.gov/drugoverdose/pdf/calculating\\_total\\_daily\\_dose\\_a.pdf](http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose_a.pdf)

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Number of Patients with:

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
High dose opioids (>=90 MME/day) (excluding MAT)	7,272	7,051	7,005	-0.7%	-3.7%
High dose benzodiazepines (>=40 DME/day)	9,655	9,236	9,229	-0.1%	-4.4%
Opioids >=90 days and <90% of days in past 6 months (excluding MAT)	13,686	13,501	13,673	1.3%	-0.1%
Opioids >=90% of days in past 6 months (excluding MAT)	24,592	23,562	23,246	-1.3%	-5.5%
Benzodiazepines >=90 days and <90% of days in past 6 months	15,950	15,142	15,008	-0.9%	-5.9%
Benzodiazepines >=90% of days in past 6 months	19,762	18,974	18,669	-1.6%	-5.5%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	1,823	1,833	1,847	0.8%	1.3%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	1,270	1,142	1,116	-2.3%	-12.1%
Concurrent opioid and benzodiazepines (>=10 days overlap)	10,869	10,460	10,163	-2.8%	-6.5%
High dose opioids (>=90 MME/day) plus benzodiazepines	1,537	1,469	1,425	-3.0%	-7.3%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	1,554	2,225	2,940	32.1%	89.2%
New Opioid Patients with at least 30 days of coverage in the past 3 months (excl MAT)	1,879	2,083	2,015	-3.3%	7.2%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	2,795	2,876	2,776	-3.5%	-0.7%

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

## I. New Mexico Prescription Monitoring Program (PMP) Measures


### New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
Total active controlled substance prescribers	3,080	3,112	3,469	11.5%	12.6%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	19	19	19	0.0%	0.0%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	75	78	84	7.7%	12.0%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,846	1,800	1,908	6.0%	3.4%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	216	227	276	21.6%	27.8%
Number of Patients with PMP reports requested by practitioners	443,881	454,655	471,013	3.6%	6.1%
% of Chronic opioid users with a PMP request in the past 3 months*	84.1%	83.3%	83.5%	0.3%	-0.7%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	61.8%	60.9%	61.4%	0.8%	-0.7%
% of New Opioid Patients with a PMP request in the past 3 months**	47.5%	45.5%	45.7%	0.5%	-3.7%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	48.2%	46.1%	46.2%	0.3%	-4.0%

\*Chronic users are those with at least 90 days of coverage in six months.

\*\*New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



## II. Medication Assisted Treatment (buprenorphine and methadone) Measures

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
Buprenorphine MAT prescribers with at least 10 treatment patients	253	264	263	-0.4%	4.0%
Buprenorphine MAT prescribers with 5 to 9 treatment patients	95	107	122	14.0%	28.4%
Buprenorphine MAT prescribers with 1 to 4 treatment patients	278	315	424	34.6%	52.5%
Buprenorphine MAT patients (>=10 days)	8,423	8,704	8,787	1.0%	4.3%
Buprenorphine MAT prescriptions filled	28,780	28,460	28,323	-0.5%	-1.6%

### Medicaid Methadone Treatment


Number of distinct individuals with methadone claims paid by NM Medicaid	5,682	5,627	5,766	2.5%	1.5%
Number of distinct NM Medicaid providers of methadone	13	13	14	7.7%	7.7%

Methadone Treatment Programs by Survey Date	Jun 2022	Mar 2023	Jun 2023		
Number of Methadone Treatment Programs	21	21	21	0.0%	0.0%
Number of Methadone Treatment Patients in those Programs	7,238	6,326	6,168	-2.5%	-14.8%

DATA Waivered provider data are as of the last month of the quarter  
After December 2022, the DATA waiver will no longer be needed to provide OUD treatment

#### Sources:

Buprenorphine MAT data: NM Prescription Monitoring Program  
Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid  
DATA Waivered providers: US DEA Diversion Control Division



### III. Naloxone Distribution and Usage Measures

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
New Enrollments in NM State Government Naloxone Programs	3,573	1,207	987	-18.2%	-72.4%
Total Number of NM Naloxone Doses distributed*	15,616	9,708	11,700	20.5%	-25.1%
Total Number of NM Reported Reversals**	648	660	858	30.0%	32.4%

Year and Quarter	2022Q2	2023Q1	2023Q2	Quarterly % Change 2023Q1 vs 2023Q2	Quarterly % Change 2022Q2 vs 2023Q2
Pharmacies Presenting Medicaid Naloxone Claims+	256	248	252	1.6%	-1.6%
Number of Medicaid Naloxone Claims Processed	3,443	4,590	1,137	-75.2%	-67.0%

\*Some naloxone doses were given to organizations and may not have been distributed in that quarter.

\*\*Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

+An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 286 outpatient Pharmacies with a NM address in 2019 according to the Board of Pharmacy.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

